ImmuneRegen files IND application for idiopathic pulmonary fibrosis drug

May 29, 2009

By Flinn Foundation

[Source:] – ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, has submitted an investigational new drug application to the FDA to begin human clinical testing of Homspera, an analog of the endogenous neurokinin substance P.

The company plans to evaluate Homspera initially as a treatment for idiopathic pulmonary fibrosis.

For more information click here.